Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary Shares, CHF 0.01 par value per share
-
Shares outstanding
-
57,458,694
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
3,013,203
-
Shares change
-
-314,245
-
Total reported value, excl. options
-
$36,946,526
-
Value change
-
-$3,838,556
-
Number of buys
-
3
-
Number of sells
-
2
-
Price
-
$12.26
Institutional Holders of Oculis Holding AG - Ordinary Shares, CHF 0.01 par value per share (OCS) as of Q3 2024
As of 30 Sep 2024 Oculis Holding AG - Ordinary Shares, CHF 0.01 par value per share (OCS) had 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 3,013,203 shares of stock of the company.
Largest 10 holders included Pivotal bioVenture Partners Investment Advisor LLC, abrdn plc, Nan Fung Group Holdings Ltd, Compagnie Lombard Odier SCmA, BANK OF AMERICA CORP /DE/, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, DUPONT CAPITAL MANAGEMENT CORP, and JPMORGAN CHASE & CO.
This table shows 10 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.